Gastrointestinal cancers in women: The role of sex hormones The relationship between sex hormones and GI cancers in women is complex, with hormones being protective or predisposing. Understanding how hormonal, genetic, and environmental factors interact could…

The relationship between sex hormones and GI cancers in women is complex, with hormones being protective or predisposing.

Understanding how hormonal, genetic, and environmental factors interact could improve #GICancer care for women.

👉 buff.ly/slaXTWA

#GISky #OncSky

Ready for Day 3 of #InSiGHT2026 ?👀

Don’t miss these exciting sessions:

🧬Session 7: Hereditary Gastric Cancer Surveillance and Management
🔬Session 8: Advances in Pancreatic Cancer Research
🧪Sessions 9 & 10: Advances in Lynch Syndrome Research

#InSiGHTCommunity #GIcancer #LynchSyndrome

Our Young InSiGHT members are off to a strong start of #InSiGHT2026!
Day 1 - Padel session full of energy & teamwork
Day 2 - Breakfast session with great conversations & new connections
And this is only the beginning! We can't wait to see this #InSiGHTCommunity grow 🌟

#GIcancer #YoungInSiGHT

The road to InSiGHT 2026 Singapore officially started! We are thrilled to begin shaping a meeting that will inspire, connect, and advance our field.

Kicking off the meeting with a Masterclass in GI Cancer Genomics by Heather Hampel.

#InSiGHT2026 #GICancer #BiennialMeeting #PublicHealth #genomics

🦠 Gastroenterology: From guidelines to gut health. Practical GI updates you can use right away — guidelines, celiac management & cancer screening.
📅May 9 | 9:30–10:55
📍ICE Congress Centre Kraków & online👉 www.mircim.one | MIRCIM #Gastroenterology #GICancer #MIRCIM

Zanidatamab Triplet May Be a “Game Changer” for the Frontline Management of HER2+ GEA | OncLive Manish A. Shah, MD, and Raji Shameem, MD, discuss potentially paradigm-shifting results from the HERIZON-GEA-01 study.

Zanidatamab Triplet May Be a “Game Changer” for the Frontline Management of HER2+ GEA @orlandohealth.bsky.social @weillcornell.bsky.social #oncology #GEA #GIcancer www.onclive.com/view/zanidat...

Frontline Retifanlimab Approaches EU Approval for Advanced Squamous Cell Carcinoma of the Anal Canal
#oncology #GIcancer

www.onclive.com/view/frontli...

Catch up on the latest Oncology Unscripted episodes with John Marshall, MD 🍃 New conversations are now live! Watch the newest episodes here 👉 https://bit.ly/3M5Tady

#GICancer #OncologyInsights

Long-term PPI use may not increase stomach cancer risk A large population-based study has found no significant association between long-term use of proton pump inhibitors and an increased risk for gastric adenocarcinoma.

#MedNews - A large population-based study has found no significant association between long-term use of proton pump inhibitors and an increased risk for gastric adenocarcinoma.

👉 buff.ly/Y2acw6V

#GICancer #PPIs

Early 2026, clear signal 📈 As John Marshall shares on Oncology Unscripted: colorectal cancer cases are rising, patients are younger, and screening gaps remain. New data and therapies mean urgency, now.

More to come: https://bit.ly/3ZDiQBg

#GICancer #OncologyInsights

✅ Identify the role of immunotherapy and targeted agents in upper GI malignancies.
✅ Recognise expected pathological response rates and postoperative management strategies in Oesophageal cancers

#OesophagealCancer #Oncology #OncoIQ #MedicalEducation #Immunotherapy #GICancer

Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies #oncology #GIcancer #medtwitter @uscnorriscancer.bsky.social
www.onclive.com/view/anti-gr...

Unpacking the FDA Approvals That Reshaped Cancer Care in 2025 #oncology #FDA #bcsm #lcsm #GIcancer
www.onclive.com/view/unpacki...

We're excited for @ascocancer.bsky.social #GI26! Stop by Dr. Steve Maron's poster to learn about a phase 2 trial of amivantamab for EGFR- or MET-amplified #gastroesophageal #adenocarcinoma. @mskcancercenter.bsky.social #GICancer

TODAY | 11:30 – 1 p.m. PST

Learn more: bit.ly/49cfzyr

Today’s the final call for late abstract submissions for #InSiGHT2026!

📅 Deadline: Jan 5

Plus, early-bird registration closes Jan 10 – don’t miss your chance to join us in Singapore!

Register now insight2026.org

#InSiGHT2026 #GIcancer #lateabstractsubmission #GIgenetics

Phase II PROCEED Trial Results: Pembrolizumab Added to Neoadjuvant Chemoradiotherapy in Esophagogastric Cancer - OncoDaily Phase II PROCEED Trial Results: Pembrolizumab Added to Neoadjuvant Chemoradiotherapy in Esophagogastric Cancer / cancer, cancer care, Cancer research, cancer

Phase II PROCEED Trial Results: Pembrolizumab Added to Neoadjuvant Chemoradiotherapy in Esophagogastric Cancer

oncodaily.com/oncolibrary/...

#GICancer #OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews

Gastrointestinal Cancer Specialist in Delhi: Why Dr. Manish Jain is the Best GI Cancer Doctor in Delhi NCR Dr Manish Jain, Best GI Surgery Specialist in Delhi NCR, Best GI Cancer Treatment in Delhi, GI Cancer doctor in Delhi NCR, Robotic GI oncosurgery, Gas

When searching for the best #GIcancer #doctor in Delhi NCR or the top GI surgery specialist in Delhi, Dr. Manish Jain's name consistently rises to the forefront.

Read More: expertgisurgeon.blogspot.com/2025/12/gast...

🔗 Read more: bit.ly/ONCOnews15D-02

#ONCOnews #OncoAlert #OncEd #OncologyNews #CancerResearch #GIcancer #ImmunoOncology

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma | OncLive Zanidatamab-based regimens improved PFS and OS vs chemotherapy in HER2+ gastroesophageal adenocarcinoma, positioning the agent as a potential new standard.

Zanidatamab Plus Chemo ± Tislelizumab Impresses in HER2+ Gastroesophageal Adenocarcinoma #GIcancer #oncology

www.onclive.com/view/zanidat...

Consistent Physical Activity Reduces Risk of Digestive System Cancers, Research Suggests Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and enhancing immune function,” researchers reported.

Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system #cancers. Published in @jamaoncology.com.

https://bit.ly/3WDdULm

#gicancer #gicsm

Consistent Physical Activity Reduces Risk of Digestive System Cancers, Research Suggests Alongside reducing body mass index, “physical activity may have systematic anticancer effect, such as improving insulin sensitivity, reducing hyperinsulinemia, lowering systemic inflammation, and enhancing immune function,” researchers reported.

Physical activity, particularly at a consistent level in line with guideline recommendations, significantly reduces both risk of and mortality from digestive system cancers. Published in @jamaoncology.com

https://bit.ly/3WDdULm

#gicsm #gicancer #GastricCancerAwaressMonth ##GCAM

Comparison of the efficacy of mFOLFOX-6 and mDCF regimens in the treatment of metastatic gastric cancer: a multicenter retrospective study - Ogur Karhan, Serdar İleri, Zuhat Urakçı, Yasin Sezgin, Ümit Yıldırım, Beyza Ünlü, Hacer Demir, Hasibe Bilge Gür, Ayşe Demirci, Melih Şimşek, Hüseyin Salih Semiz, Savaş Gökçek, Nilgün Yıldırım, Tuğçe Kübra Güneş, Abdilkerim Oyman, Tolga Doğan, Gamze Gököz Doğu, Yusuf İlhan, Özgür Tanrıverdi, Ali İnal, Nadiye Sever, Ezgi Türkoğlu, Tugay Avcı, Sadi Kerem Okutur, Pınar Peker, Doğan Bayram, Onur Yazdan Balçık, Pervin Can Şancı, Seray Saray, Pınar Çoban Eşdur, İsmail Beypınar, Sezai Tunç, 2025 Background: Metastatic gastric cancer (GC) and gastroesophageal junction (GEJ) cancer are associated with a poor prognosis. Recent advancements in treatment hav...

🚨 A multicenter study compares mFOLFOX-6 vs. mDCF in metastatic gastric & GEJ cancer. buff.ly/1NsLmel
🔍 Similar efficacy
📉 Lower toxicity with mFOLFOX-6
📊 493 patients across 25 hospitals
Is doublet chemo the new standard?
#GastricCancer #Oncology #GIcancer #Chemotherapy #CancerResearch

OncLive® and the Ruesch Center for the Cure of Gastrointestinal Cancers announce recipients of the 2025 Luminary Awards in GI Cancer | OncLive OncLive® and the Ruesch Center at Georgetown Lombardi announce the 2025 Luminary Award winners in gastrointestinal cancers.

OncLive and the @rueschcenter.bsky.social for the Cure of Gastrointestinal Cancers announce recipients of the 2025 Luminary Awards in #GICancer

www.onclive.com/view/onclive...

#ESMO25: Positive efficacy results without safety concerns seen with NW-301V, a TCR-T therapy targeting KRAS G12V, in patients with KRAS G12V-mutant advanced #GICancer in a phase I #ClinicalTrial.
#ESMODailyReporter🔗 https://ow.ly/jouK50XjATp


Jon Lim, MRCP PhD

Annual Scientific Meeting The AGITG Annual Scientific Meeting provides GI cancer researchers and specialists the opportunity to present recent research into GI cancers and discuss current challenges and potential solutions…

🧬 There's still time to register for the #AGITG 27th Annual Scientific Meeting — 24-27 November 2025 in Tarntanya / Adelaide: t.ly/nCn4Y

You can learn more about the program highlights in our Special Preview podcast here: t.ly/ly9fx #GICancer #GIOncology #CancerResearch #Collaboration #MedEd

ICI Use Does Not Significantly Affect EOL Outcomes in HCC | OncLive Margaret Wheless, MD, discusses findings from a study of end-of-life outcomes and health care resource utilization in ICI-treated HCC.

ICI Use Does Not Significantly Affect EOL Outcomes in HCC
@vumchak.bsky.social #oncology #hcc #GIcancer www.onclive.com/view/ici-use...

🎙️ NEW PODCAST! A/Prof Sina Vatandoust & A/Prof Margaret Lee join Rachael Babin to preview #AGITG ASM 2025 — exploring global collaboration & innovation in GI oncology.
Listen here: t.ly/ZKF16 or wherever you get your podcasts| @agitg.bsky.social #GIcancer #CancerResearch #OncologyPodcast #Oncology

Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer | OncLive regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

Regorafenib Plus Nivolumab Yields Nonsuperior Survival in Refractory Gastric/GEJ Cancer #ESMO25 #GIcancer #oncology

www.onclive.com/view/regoraf...

WELCOME To #ESMO25: The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.

The OncoAlert #GICancer Faculty, led by Dr. Akkus🇹🇷 , Dr. Hornstein🇺🇸 , Dr. Balsa🇪🇸 , Dr. Cifuentes 🇨🇴 & Dr. Morgan🇺🇸 have selected the OncoAlert TOP 🔟 #ESMO25 Abstracts In #CRC , #HCC, #GEJC #ColonCancer to be presented in Berlin🇩🇪 Picked using a Delphi System to establish our picks.